SCYX

Ibrexafungerp Developments: The FDA has lifted the clinical hold on ibrexafungerp, allowing SCYNEXIS to resume the Phase 3 MARIO study for invasive candidiasis treatment, despite a disagreement with GSK regarding the study's continuation. Hansoh has received approval in China for ibrexafungerp, and SCYNEXIS will benefit from milestone payments and royalties upon commercialization.

Financial Overview and Future Plans: SCYNEXIS reported a net loss of $5.4 million for Q1 2025, with cash reserves projected to last until Q3 2026. The company is also advancing its second-generation fungicide candidate, SCY-247, with initial Phase 1 data expected in Q3 2025, while continuing to address the rising threat of drug-resistant fungal infections.

SCY-247 Presentation: SCYNEXIS, Inc. announced the presentation of promising preclinical efficacy data for its antifungal candidate SCY-247 at the ESCMID Global conference, highlighting its effectiveness against drug-resistant fungal infections, particularly various strains of Candida.

Antifungal Activity Findings: Studies presented showed that SCY-247 exhibits strong in vitro activity against multiple clinically relevant yeast isolates, including those resistant to existing treatments, indicating its potential as a new option in combating systemic fungal diseases.

SCY-247 Development and Clinical Trials: SCYNEXIS is progressing with the Phase 1 trial of its second-generation antifungal SCY-247, with results expected in Q3 2025. The company is also preparing to restart the Phase 3 MARIO study for invasive candidiasis pending FDA approval.

Financial Performance and Future Outlook: For the year ending December 31, 2024, SCYNEXIS reported a net loss of $21.3 million and had cash reserves of $75.1 million, projected to sustain operations into Q3 2026.